Sickle cell disease affects over 250 million people worldwide. It is a multifaceted disease characterized by chronic hemolytic anemia, unpredictable episodes of pain, and widespread organ damage (Reviewed in Kato et al. 2018) and can be hereditarily passed on from an infected parent to a child. Early detection is key to improving the quality of life of those affected and help reduce the number of children affected.
The long-term availability of reliable antibodies for point-of-care tests is among the biggest challenges for diagnostic companies. Rockland’s scalable in-house manufacturing capabilities make us a reliable partner for the supply of these critical reagents to the industry.
Sickle Cell Disease Screening Using Rockland Lateral Flow Antibodies
Lateral flow assays can be used to diagnose and monitor the severity of hemoglobin disorders by testing blood samples for markers such as hemoglobin beta S. They are simple and portable point-of-care screening tools that can help identify disease before the onset of symptoms so that treatment regimens can be set. Recently, two scientific papers were published highlighting lateral flow assays as diagnostic tools for the detection of sickle cell anemia in low to middle-income countries (LMICs)2,3. Both publications rely on Rockland's hemoglobin antibodies (200-301-GS4 and 200-301-GS5) to provide scalable and cost-effective solutions requiring only a single drop of whole blood as the sample. Rockland's antibodies can be used to rapidly detect various diseases within the same lateral flow assay:
Figure: Example layout for a lateral flow assay with 3 indicators to detect different states of sickle cell disease.
Sickle Cell Disease Antibodies
With the support of the National Heart, Lung, and Blood Institute (NHLBI), Rockland has successfully developed a set of antibodies for the detection of hemoglobin variants. These antibodies have been designed for use in lateral flow assays and are suitable for a wide range of immunological applications.
| Product | Item No. | Reactivity | LFA Function | Applications |
| Hemoglobin Antibody | 200-301-MV4 | Human | Detection | LFA, WB, ELISA |
| Hemoglobin A (beta chain) Antibody | 200-301-GS4 | Human | Capture | LFA, WB, ELISA, FC |
| Hemoglobin beta A-2 Antibody | 200-301-GS8 | Human | N/A | LFA, WB, ELISA |
| Hemoglobin beta C Antibody | 200-301-GS7 | Human | Capture | LFA, WB, ELISA |
| Hemoglobin beta F Antibody | 200-301-GS6 | Human | N/A | LFA, WB, ELISA |
| Hemoglobin beta S Antibody | 200-301-GS5 | Human | Capture | LFA, WB, ELISA, FC |
Sickle Cell Disease Peptides
| Product | Item No. | Synonyms |
| Hemoglobin A (beta chain) Control Peptide | 000-001-GS4 | Hbβ Control Peptide, Hemoglobin beta subunit, HBB |
| Hemoglobin A-2 Control Peptide | 000-001-GS8 | HbA-2 Control Peptide, Hemoglobin Subunit Delta, Hemoglobin Delta Chain 4, Delta-Globin 4, HbD |
| Hemoglobin C Control Peptide | 000-001-GS7 | HbC Control Peptide, Hemoglobin beta subunit C variant, HbBc, HbC |
| Hemoglobin F Control Peptide | 000-001-GS6 | HbF Control Peptide, Hemoglobin delta subunit, HBG1, HBG2 |
| Hemoglobin S Control Peptide | 000-001-GS5 | HbS Control Peptide, Hemoglobin beta subunit sickle mutant, HBS, HBBs |
Sickle Cell Disease
Sickle cell disease (SCD), thalassemias, and other hemoglobinopathies occur when aberrant forms of hemoglobin are expressed in humans. Hemoglobin functions as the oxygen-carrying molecule in red blood cells and gives blood its characteristic color. Functional adult hemoglobin (HbA) is a heterotetramer composed of 2 α-globin and 2 β-globin protein subunits. Sickle cell disease is caused by a mutation in the β-globin subunit encoded by the HBB gene that leads to the production of abnormal hemoglobin, known as hemoglobin beta S (HbS).
Common Hemoglobin Variants
HbA
HbA-2
HbC
HbF
HbS
References
Interested in antibodies for lateral flow assays?
Talk with us to find out how we can help move your research forward.